PD-L1 Status in Refractory Lymphomas

• Semir Vranic,

  Affiliations Department of Pathology, Clinical Center, University of Sarajevo, Sarajevo, Bosnia and Herzegovina, School of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina

  http://orcid.org/0000-0001-9743-7265

  ⨯
• Nilanjan Ghosh,

  Affiliation Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, North Carolina, United States of America

  ⨯
• Jeffery Kimbrough,

  Affiliation Caris Life Sciences, Phoenix, Arizona, United States of America

  ⨯
• Nurija Bilalovic,

  Affiliation Department of Pathology, Clinical Center, University of Sarajevo, Sarajevo, Bosnia and Herzegovina

  ⨯
• Ryan Bender,

  Affiliation Caris Life Sciences, Phoenix, Arizona, United States of America

  ⨯
• David Arguello,

  Affiliation Caris Life Sciences, Phoenix, Arizona, United States of America

  ⨯
• Yvonne Veloso,

  Affiliation Caris Life Sciences, Phoenix, Arizona, United States of America

  ⨯
• Aida Dizdarevic,

  Affiliation Department of Hematology, Clinical Center, University of Sarajevo, Sarajevo, Bosnia and Herzegovina

  ⨯
• Zoran Gatalica

  * E-mail: semir.vranic@gmail.com

  Affiliation Caris Life Sciences, Phoenix, Arizona, United States of America

  ⨯